Floatz logo

Polyiclc

Ocular Melanoma

Craig L Slingluff, JrPhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Ocular Melanoma cohort.

Asset / SponsorPhaseRating
BELZUPACAP SAROTALOCAN
Aura Biosciences
Phase 2BB
Ipilimumab
University of Michigan Rogel Cancer Center
Phase 2BB
Nivolumab
University of Michigan Rogel Cancer Center
Phase 2B
Aflibercept
Centre Hospitalier Universitaire de Nice
Phase 3B
Bel-Sar
Aura Biosciences
Phase 3B

View all 25 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
Metastatic Triple-Negative Breast CarcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →